Development of a DC-targeting Salmonella- amplifying RNA vector platform co-delivering dual antigens and adjuvants...

Avian influenza virus primarily invades the respiratory mucosa, necessitating the establishment of a robust mucosal secretory IgA (sIgA) barrier. However, the efficacy of avian mucosal vaccines is often hindered by inefficient antigen uptake and immune tolerance. Consequently, modern vaccine strategies focus on active targeting delivery, immune microenvironment remodeling, and activation of multifaceted immune responses. The immunogenicity and molecular mechanisms of a novel Salmonella-delivered self-amplifying RNA (saRNA) vector platform were evaluated in this study. This platform integrates bacterial surface display of a dendritic cell (DC)-targeting nanobody (Nb-phage54 via LppOmpA) with co-expression of molecular adjuvants against H9N2 influenza. The expression of HA1 and NA antigens from recombinant plasmids (pYL673, pYL679, and pYL681) was confirmed using confocal microscopy and Western blot analysis. In vitro assays revealed that the Nb-mediated targeting strain (S673) significantly increased invasion efficiency into bone marrow-derived dendritic cells and up-regulated the transcription of CCL5, CCR7, CD83, and CD86, effectively promoting DC maturation. Transcriptomic analysis (RNA-seq) revealed divergent mechanisms among vaccine candidates. The non-targeting group (S615) primarily activated antiviral innate pathways, such as JAK-STAT, whereas the targeting group (S673) significantly improved antigen processing, presentation, and natural killer cell-mediated cytotoxicity. Moreover, the adjuvant-integrated groups, S679 (CpG) and S681 (FliC), specifically triggered Toll-like receptor-21 (TLR21) and TLR5 signaling cascades by increasing cell adhesion, phagocytosis, and transmembrane signal transduction. Animal trials revealed that the targeted adjuvant vectors (S679 and S681) significantly elevated serum IgG and intestinal mucosal sIgA titers in chickens. The S679 group excelled in stimulating lymphocyte proliferation and secreting interferon-gamma and interleukin-4, indicating a potent Th1/Th2 balanced response. Challenge experiments with H9N2 virus confirmed that S679 and S681 effectively mitigated weight loss, shortened the viral shedding window, reduced viral loads in the lungs and trachea, and significantly alleviated respiratory pathological damage and inflammation. The DC-targeting saRNA-Salmonella vector developed in this study, particularly when synergized with CpG or FliC adjuvants, induced robust systemic, mucosal, and cellular immunity by activating specific intracellular signaling cascades. These findings demonstrate that this platform is a highly effective and promising candidate strategy for preventing and controlling H9N2 avian influenza.